ANGPTL3 and coronary artery disorder: Whole-exome sequencing performed as a part of the DiscovEHR study revealed that persons heterozygous for ANGPTL3 loss-of-function (LoF) variants had approximately 50% lower ANGPTL3 levels compared to non-carriers as well as 39% lower odds of CAD [59].